Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 1/2007

01.01.2007 | Review Article

Thirty Years of Clinical Experience with Carbamazepine in the Treatment of Bipolar Illness

Principles and Practice

verfasst von: Robert M. Post, Prof. Terence A. Ketter, Thomas Uhde, James C. Ballenger

Erschienen in: CNS Drugs | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Carbamazepine began to be studied in a systematic fashion in the 1970s and became more widely used in the treatment of bipolar disorder in the 1980s. Interest in carbamazepine has been renewed by (i) the recent US FDA approval of a long-acting preparation for the treatment of acute mania; (ii) studies suggesting some efficacy in bipolar depression; and (iii) evidence of prophylactic efficacy in some difficult-to-treat subtypes of bipolar illness. A series of double-blind controlled studies of the drug were conducted at the US National Institute of Mental Health from the mid-1970s to the mid-1990s. This review summarises our experience in the context of the current literature on the clinical efficacy, adverse effects and pharmacokinetic interactions of carbamazepine.
Carbamazepine has an important and still evolving place in the treatment of acute mania and long-term prophylaxis. It may be useful in individuals with symptoms that are not responsive to other treatments and in some subtypes of bipolar disorder that are not typically responsive to a more traditional agent such as lithium. These subtypes might include those patients with bipolar II disorder, dysphoric mania, substance abuse co-morbidity, mood incongruent delusions, and a negative family history of bipolar illness in first-degree relatives. In addition, carbamazepine may be useful in patients who do not adequately tolerate other interventions as a result of adverse effects, such as weight gain, tremor, diabetes insipidus or polycystic ovarian syndrome.
We review our clinical and research experience with carbamazepine alone and in combination with lithium, valproic acid and other agents in complex combination treatment of bipolar illness. More precise clinical and biological predictors and correlates of individual clinical responsiveness to carbamazepine and other mood stabilisers are eagerly awaited.
Fußnoten
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literatur
1.
Ballenger JC, Post RM. Kindling as a model for alcohol withdrawal syndromes. Br J Psychiatry 1978; 133: 1–14PubMed
2.
Post RM, Rubinow DR, Ballenger JC. Conditioning, sensitization, and kindling: implications for the course of affective illness. In: Post RM, Ballenger JC, editors. Neurobiology of mood disorders. Baltimore (MD): Williams and Wilkins, 1984: 432–66
3.
Post RM, Uhde TW, Ballenger JC, et al. Carbamazepine, temporal lobe epilepsy, and manic-depressive illness. In: Mendlewicz J, Van Praag HM, editors. Advances in biological psychiatry. Vol. 8: temporal lobe epilepsy, mania, schizophrenia, and the limbic system. Basel: S. Karger AG, 1982: 117–56
4.
Post RM, Uhde TW, Putnam FW, et al. Kindling and carbamazepine in affective illness. J Nerv Ment Dis 1982; 170: 717–31PubMed
5.
Albright PS, Burnham WM. Development of a new pharmacological seizure model: effects of anticonvulsants on cortical-and amygdala-kindled seizures in the rat. Epilepsia 1980; 21: 681–9PubMed
6.
Babington RG. The pharmacology of kindling. In: Hanin I, Usdin E, editors. Animal models of psychiatry and neurology. Oxford: Pergamon Press, 1977: 141–9
7.
Papez JW. A proposed mechanism of emotion. Arch Neurol Psychiatry 1937; 38: 725–43
8.
MacLean PD. The triune brain in conflict. Psychother Psychosom 1977; 28: 207–20PubMed
9.
Marjerrison G, Jedlicki SM, Keogh RP, et al. Carbamazepine: behavioral, anticonvulsant and EEG effects in chronically-hospitalized epileptics. Dis Nerv Syst 1968; 29: 133–6PubMed
10.
Penry JK, Daly DD. Complex partial seizures and their treatment: advances in neurology. Vol. 11. New York: Raven Press, 1975
11.
Post RM, Uhde TW. Are the psychotropic effects of carbamazepine in manic-depressive illness mediated through the limbic system? Psychiatr J Univ Ottawa 1985; 10: 205–19
12.
Dalby MA. Antiepileptic and psychotropic effect of carbamazepine(Tegretol) in the treatment of psychomotor epilepsy. Epilepsia 1971; 12: 325–34PubMed
13.
Dalby MA. Behavioral effects of carbamazepine. In: Penry JK, Daly DD, editors. Complex partial seizures and their treatment: advances in neurology. Vol. 11. New York: Raven Press, 1975: 331–43
14.
Okuma T, Kishimoto A, Inoue K, et al. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis: a preliminary report. Folia Psychiatr Neurol Jpn 1973; 27: 283–97PubMed
15.
Okuma T, Kishimoto A. A history of investigation on the mood stabilizing effect of carbamazepine in Japan. Psychiatry Clin Neurosci 1998; 52: 3–12PubMed
16.
Takezaki H, Hanaoka M. The use of carbamazepine (Tegretol) in the control of manic-depressive psychosis and other manic, depressive states. Clin Psychiatry 1971; 13: 173–82
17.
Ballenger JC, Post RM. Therapeutic effects of carbamazepine in affective illness: preliminary report. Commun Psychopharmacol 1978; 2: 159–75PubMed
18.
Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980; 137: 782–90PubMed
19.
Post RM, Uhde TW, Ballenger JC, et al. Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry 1983; 140: 1602–4PubMed
20.
Post RM, Uhde TW, Roy-Byrne PP, et al. Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143: 29–34PubMed
21.
Post RM, Uhde TW, Roy-Byrne PP, et al. Correlates of anti-manic response to carbamazepine. Psychiatry Res 1987; 21: 71–83PubMed
22.
Post RM, Luckenbaugh DA. Unique design issues in clinical trials of patients with bipolar affective disorder. J Psychiatr Res 2003; 37: 61–73PubMed
23.
Okuma T, Inanaga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharm 1979; 66: 211–7
24.
Grossi E, Sacchetti E, Vita A, et al. Carbamazepine vs chlorpromazine in mania: a double-blind trial. In: Emrich HM, Okuma T, Muller AA, editors. Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica, 1984: 177–87
25.
Klein E, Bental E, Lerer B, et al. Carbamazepine and haloperidol vs placebo and haloperidol in excited psychoses. Arch Gen Psychiatry 1984; 41: 165–70PubMed
26.
Goncalves N, Stoll KD. Carbamazepine in manic syndromes: a controlled double-blind study. Nervenarzt 1985; 56: 43–7PubMed
27.
Lenzi A, Lazzerini F, Grossi E, et al. Use of carbamazepine in acute psychosis: a controlled study. J Int Med Res 1986; 14: 78–84PubMed
28.
Stoll KD, Bisson HE, Fischer E, et al. Carbamazepine versus haloperidol in manic syndromes: first report of a multicentric study in Germany. In: Shagass C, Josiassen RC, Bridger WH, et al., editors. Biological Psychiatry 1985. Amsterdam: Elsevier Science Publishing Co. Inc., 1986: 332–4
29.
Desai NG, Gangadhar BN, Channabasavanna SM, et al. Carbamazepine hastens therapeutic action of lithium in mania. Proceedings of the International Conference on New Directions in Affective Disorders. 1987 Apr 5–9; Jerusalem. New York: Springer Verlag, 1987: 97
30.
Lerer B, Moore N, Meyendorff E, et al. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987; 48: 89–93PubMed
31.
Lusznat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988; 153:198–204PubMed
32.
Okuma T, Yamashita I, Takahashi R, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 1989; 80: 250–9PubMed
33.
Brown D, Silverstone T, Cookson J. Carbamazepine compared to haloperidol in acute mania. Int Clin Psychopharmacol 1989; 4: 229–38PubMed
34.
Moller HJ, Kissling W, Riehl T, et al. Double-blind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. Prog Neuropsychopharmacol Biol Psych 1989; 13: 127–36
35.
Okuma T, Yamashita I, Takahashi R, et al. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 1990; 23: 143–50PubMed
36.
Small JG, Klapper MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991; 48: 915–21PubMed
37.
Weisler RH, Kalali AH, Ketter TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65: 478–84PubMed
38.
Weisler RH, Keck Jr PE, Swann AC, et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005; 66: 323–30PubMed
39.
Zhang ZJ, Kang WH, Tan QR, et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. J Psychiatr Res 2007; 41: 360–9PubMed
40.
Post RM, Speer AM. A brief history of anticonvulsant use in affective disorders. In: Trimble MR, Schmitz B, editors. Scizures, affective disorders and anticonvulsant drugs. Surrey: Clarius Press, 2002: 53–81
41.
Licht RW. Drug treatment of mania: a critical review. Acta Psychiatr Scand 1998; 97: 387–97PubMed
42.
Greil W, Kleindienst N, Erazo N, et al. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998; 18: 455–60PubMed
43.
Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance study of lithium vs divalproex in rapid cycling bipolar disorder. Am J Psychiatry 2005; 162: 2152–61PubMed
44.
Post RM, Berrettini WH, Uhde TW, et al. Selective response to the anticonvulsant carbamazepine in manic-depressive illness: a case study. J Clin Psychopharmacol 1984; 4: 178–85PubMed
45.
Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000; 61: 9–15PubMed
46.
Frangou S, Raymont V, Bettany D. The Maudsley bipolar disorder project: a survey of psychotropic prescribing patterns in bipolar I disorder. Bipolar Disord 2002; 4: 378–85PubMed
47.
Post RM, Speer AM, Leverich GS. Complex combination therapy: the evolution toward rational polypharmacy in lithium-resistant bipolar illness. In: Akiskal HS, Tohen M, editors. Bipolar psychopharmacotherapy: caring for the patient. London: John Wiley & Sons Ltd, 2006: 135–67
48.
Kowatch RA, Sethuraman G, Hume JH, et al. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry 2003; 53: 978–84PubMed
49.
Levine J, Chengappa KN, Brar JS, et al. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord 2000; 2: 120–30PubMed
50.
Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 213–35PubMed
51.
Keck Jr PE, Perlis RH, Otto MW, et al. The expert consensus guideline series: treatment of bipolar disorder 2004. Postgrad Med Special Rep 2004 Dec: 1–120
52.
Post RM, Speer AM, Obrocea GV, et al. Acute and prophylactic effects of anticonvulsants in bipolar depression. Clin Neurosci Res 2002; 2: 228–51
53.
Hartong EG, Moleman P, Hoogduin CA, et al. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003; 64: 144–51PubMed
54.
Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470–8PubMed
55.
Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392–400PubMed
56.
Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013–24PubMed
57.
Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 2002; 63: 146–51PubMed
58.
Post RM, Altshuler LL. Mood disorders: treatment of bipolar disorders. In: Sadock BJ, Sadock VA, editors. Kaplan & Sadock’s comprehensive textbook of psychiatry. Philadelphia (PA): Lippincott Williams & Wilkins, 2005: 1661–707
59.
Hogan RE, Garnett WR, Thadani VM. Tolerability and effects on quality of life of twice-daily extended-release carbamazepine in adults with seizure disorders: an open-label, 12- to 36-month continuation study. Clin Ther 2003; 25: 2586–96PubMed
60.
Post RM. Extended-release carbamazepine: targeting acute bipolar mania. Curr Psychiatry 2005; 4: 72–80
61.
Post RM, Weiss SR, Chuang DM. Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium. J Clin Psychopharmacol 1992; 12: 23–35S
62.
Post RM, Chalecka-Franaszek E, Hough C. Mechanisms of action of anticonvulsants and new mood stabilizers. In: Soares JC, Gershon S, editors. Handbook of medical psychiatry. New York: Marcel Dekker, 2003: 767–91
63.
Post RM, Chuang D-M. Mechanism of action of lithium: comparison and contrast with carbamazepine. In: Birch NJ, editor. Lithium and the cell: pharmacology and biochemistry. London: Academic Press, 1991: 199–241
64.
Post RM, Weiss SRB, Chuang D-M, et al. Mechanisms of action of carbamazepine in seizure and affective disorders. In: Joffe RT, Calabrese JR, editors. Anticonvulsants in mood disorders. New York: Marcel Dekker, Inc., 1994: 43–92
65.
Post RM, Weiss SRB, Clark M, et al. Lithium, carbamazepine, and valproate in affective illness: biochemical and neurobiological mechanisms. In: Manji H, Bowden CL, Belmaker RH, editors. Bipolar medications: mechanisms of action. Washington,DC: American Psychiatric Press, 2000: 219–48
66.
Post RM, Leverich GS, Rosoff AS, et al. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol 1990; 10: 318–27PubMed
67.
Weiss SR, Clark M, Rosen JB, et al. Contingent tolerance to the anticonvulsant effects of carbamazepine: relationship to loss of endogenous adaptive mechanisms. Brain Res Brain Res Rev 1995; 20: 305–25PubMed
68.
Post RM. Prophylaxis of bipolar affective disorders. Intl Rev Psych 1990; 2: 277–320
69.
Post RM, Frye MA, Denicoff KD, et al. Anticonvulsants in the long-term prophylaxis of depression. In: Honig A, Van Praag HM, editors. Depression: neurobiological, psychopathological and therapeutic advances. Sussex: John Wiley & Sons, 1997: 483–98
70.
Pazzaglia PJ, Post RM. Contingent tolerance and reresponse to carbamazepine: a case study in a patient with trigeminal neuralgia and bipolar disorder. J Neuropsychiatry Clin Neurosci 1992; 4: 76–81PubMed
71.
Post RM, Weiss SRB. Convergences in course of illness and treatments of the epilepsies and recurrent affective disorders. Clin Electroencephalogr 2004; 35: 14–24
72.
Post RM, Uhde TW, Ballenger JC, et al. Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF: relationship to antidepressant response. Arch Gen Psychiatry 1983; 40: 673–6PubMed
73.
Post RM, Uhde TW, Wolff EA. Profile of clinical efficacy and side effects of carbamazepine in psychiatric illness: relationship to blood and CSF levels of carbamazepine and its 10,11-epoxide metabolite. Acta Psychiatr Scand 1984; 69: 104–20
74.
Ketter TA, Pazzaglia PJ, Post RM. Synergy of carbamazepine and valproic acid in affective illness: case report and review of the literature. J Clin Psychopharmacol 1992; 12: 276–81PubMed
75.
Ketter TA, Wang PW, Post RM. Carbamazepine and oxcar-bazepine. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 2004: 581–606
76.
Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995; 15: 387–98PubMed
77.
Lammers MW, Hekster YA, Keyser A, et al. Neither dosage nor serum levels of antiepileptic drugs are predictive for efficacy and adverse effects. Pharm World Sci 1995; 17: 201–6PubMed
78.
Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide: an update. Clin Pharmacokinet 1986; 11: 177–98PubMed
79.
Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine: part I. J Clin Psychopharmacol 1991; 11: 198–203PubMed
80.
Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine: part II. J Clin Psychopharmacol 1991; 11: 306–13PubMed
81.
Ketter TA, Frye MA, Cora-Locatelli G, et al. Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol 1999; 19: 511–32PubMed
82.
Hesslinger B, Normann C, Langosch JM, et al. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 1999; 19: 310–5PubMed
83.
Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania: international, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182: 141–7PubMed
84.
Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002; 16: 263–72PubMed
85.
Kramlinger KG, Phillips KA, Post RM. Rash complicating carbamazepine treatment. J Clin Psychopharmacol 1994; 14: 408–13PubMed
86.
Ketter TA, Kalali AH, Weisler RH. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65: 668–73PubMed
87.
Vick NA. Suppression of carbamazepine-induced skin rash with prednisone [letter]. N Engl J Med 1983; 309: 1193–4PubMed
88.
Murphy JM, Mashman J, Miller JD, et al. Suppression of carbamazepine-induced rash with prednisone. Neurology 1991; 41: 144–5PubMed
89.
Coombes BW. Stevens-Johnson syndrome associated with carbamazepine (Tegretol). Med J Aust 1965; 1: 895–6
90.
Rose SJ. Severe hypersensitivity secondary to extended carbamazepine administration [letter]. Clin Pharm 1985; 4: 19, 23PubMed
91.
Sobotka JL, Alexander B, Cook BL. A review of carbamazepine’ s hematologic reactions and monitoring recommendations. DICP 1990; 24: 1214–9PubMed
92.
Joffe RT, Post RM, Roy-Byrne PP, et al. Hematological effects of carbamazepine in patients with affective illness. Am J Psychiatry 1985; 142: 1196–9PubMed
93.
Kramlinger KG, Post RM. Addition of lithium carbonate to carbamazepine: hematological and thyroid effects. Am J Psychiatry 1990; 147: 615–20PubMed
94.
Boggs DR, Joyce RA. The hematopoietic effects of lithium. Semin Hematol 1983; 20: 129–38PubMed
95.
Gram L, Bentsen KD. Hepatic toxicity of antiepileptic drugs: a review. Acta Neurol Scand Suppl 1983; 97: 81–90PubMed
96.
Van Amelsvoort T, Bakshi R, Devaux CB, et al. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35: 181–8PubMed
97.
Uhde TW, Post RM. Effects of carbamazepine on serum electrolytes: clinical and theoretical implications. J Clin Psychopharmacol 1983; 3: 103–6PubMed
98.
Joffe RT, Post RM, Uhde TW. Effects of carbamazepine on serum electrolytes in affectively ill patients. Psychol Med 1986; 16: 331–5PubMed
99.
Brewerton TD, Jackson CW. Prophylaxis of carbamazepine-induced hyponatremia by demeclocycline in six patients. J Clin Psychiatry 1994; 55: 249–51PubMed
100.
Vieweg V, Glick JL, Herring S, et al. Absence of carbamazepine-induced hyponatremia among patients also given lithium. Am J Psychiatry 1987; 144: 943–7PubMed
101.
Gold PW, Robertson GL, Ballenger JC, et al. Carbamazepine diminishes the sensitivity of the plasma arginine vasopressin response to osmotic stimulation. J Clin Endocrinol Metab 1983; 57: 952–7PubMed
102.
Forrest Jr JN, Cohen AD, Torretti J, et al. On the mechanism of lithium-induced diabetes insipidus in man and the rat. J Clin Invest 1974; 53: 1115–23PubMedPubMedCentral
103.
Brown DW, Ketter TA, Crumlish J, et al. Carbamazepine-induced increases in total serum cholesterol: clinical and theoretical implications. J Clin Psychopharmacol 1992; 12: 431–7PubMed
104.
O’Neill B, Callaghan N, Stapleton M, et al. Serum elevation of high density lipoprotein (HDL) cholesterol in epileptic patients taking carbamazepine or phenytoin. Acta Neurol Scand 1982; 65: 104–9PubMed
105.
Bramswig S, Sudhop T, Luers C, et al. Lipoprotein(a) concentration increases during treatment with carbamazepine. Epilepsia 2003; 44: 457–60PubMed
106.
Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989; 320: 1661–6PubMed
107.
Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324: 674–7PubMed
108.
Sitland-Marken PA, Rickman LA, Wells BG, et al. Pharmacologic management of acute mania in pregnancy. J Clin Psychopharmacol 1989; 9: 78–87PubMed
109.
Froescher W, Eichelbaum M, Niesen M, et al. Carbamazepine levels in breast milk. Ther Drag Monit 1984; 6: 266–71
110.
Kuhnz W, Jager-Roman E, Rating D, et al. Carbamazepine and carbamazepine-10,11-epoxide during pregnancy and postnatal period in epileptic mothers and their nursed infants: pharma-cokinetics and clinical effects. Pediatric Pharmacol 1983; 3: 199–208
111.
Pynnonen S, Kanto J, Sillanpaa M, et al. Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. Acta Pharmacol Toxicol (Copenh) 1977; 41: 244–53
112.
Shimoyama R, Ohkubo T, Sugawara K. Monitoring of carbamazepine and carbamazepine 10,11-epoxide in breast milk and plasma by high-performance liquid chromatography. Ann Clin Biochem 2000; 37: 210–5PubMed
113.
Frey B, Braegger CP, Ghelfi D. Neonatal cholestatic hepatitis from carbamazepine exposure during pregnancy and breast feeding. Ann Pharmacother 2002; 36: 644–7PubMed
114.
Post RM. Valproate use in psychiatry: a focus on bipolar illness. In: Loscher W, editor. Valproate. Basel: Birkhauser Verlag, 1999: 167–201
115.
Post RM, Frye MA. Carbamazepine. In: Sadock BJ, Sadock VA, editors. Kaplan & Sadock’s comprehensive textbook of psychiatry. Philadelphia (PA): Lippincott Williams & Wilkins, 2005: 2732–46
116.
Calabrese JR, Vieta E, Shelton MD. Latest maintenance data on lamotrigine in bipolar disorder. Eur Neuropsychopharmacol 2003; 13 Suppl. 2: 57–66
117.
Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992; 327: 765–71PubMed
118.
Joffe RT, Post RM, Uhde TW. Effect of carbamazepine on body weight in affectively ill patients. J Clin Psychiatry 1986; 47: 313–4PubMed
119.
Denicoff KD, Smith-Jackson EE, Bryan AL, et al. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997; 154: 1456–8PubMed
120.
Rasgon N. The relationship between polycystic ovary syndrome and antiepileptic drags: a review of the evidence. J Clin Psychopharmacol 2004; 24: 322–34PubMed
121.
Isojarvi JI, Tauboll E, Tapanainen JS, et al. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia 2001; 42: 305–10PubMed
122.
O’Donovan C, Kusumakar V, Graves GR, et al. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002; 63: 322–30PubMed
123.
Rasgon NL, Altshuler LL, Fairbanks L, et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005; 7: 246–59PubMed
124.
MacPhee GJ, Larkin JG, Butler E. Circulating hormones and pituitary responsiveness in young epileptic men receiving long-term antiepileptic medication. Epilepsia 1988; 29: 468–75PubMed
125.
Morrell MJ. Reproductive and metabolic disorders in women with epilepsy. Epilepsia 2003; 44 Suppl. 4: 11–20
126.
Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345: 476–9PubMed
127.
Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607–14PubMed
128.
Yang JD, Elphick M, Sharpley AL, et al. Effects of carbamazepine on sleep in healthy volunteers. Biol Psychiatry 1989; 26: 324–8PubMed
129.
Drake ME, Pakalnis A, Bogner JE, et al. Effects of antiepileptic drug monotherapy on nocturnal sleep. Epilepsia 1988; 29: 687
130.
Lipper S, Davidson JRT, Grady TA, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 1986; 27: 849–54PubMed
131.
Marangell LB, George MS, Bissette G, et al. Carbamazepine increases cerebrospinal fluid thyrotropin-releasing hormone levels in affectively ill patients. Arch Gen Psychiatry 1994; 51: 625–8PubMed
132.
Strandjord RE, Aanderad S, Myking OL, et al. Influence of carbamazepine on serum thyroxine and triiodothyronine in patients with epilepsy. Acta Neurol Scand 1981; 63: 111–21PubMed
133.
Joffe RT, Gold PW, Uhde TW, et al. The effects of carbamazepine on the thyrotropin response to thyrotropin-releasing hormone. Psychiatry Res 1984; 12: 161–6PubMed
134.
Roy-Byrne PP, Joffe RT, Uhde TW, et al. Carbamazepine and thyroid function in affectively ill patients. Clinical and theoretical implications. Arch Gen Psychiatry 1984; 41: 1150–3PubMed
135.
Post RM, Rubinow DR, Uhde TW, et al. Dopaminergic effects of carbamazepine. Relationship to clinical response in affective illness. Arch Gen Psychiatry 1986; 43: 392–6PubMed
136.
Silberman EK, Post RM, Nurnberger J, et al. Transient sensory, cognitive and affective phenomena in affective illness: a comparison with complex partial epilepsy. Br J Psychiatry 1985; 146: 81–9PubMed
137.
Ali SO, Denicoff KD, Ketter TA, et al. Psychosensory symptoms in bipolar disorder. Neuropsychiatry Neuropsychol Behav Neurol 1997; 10: 223–31PubMed
138.
Hayes SG, Goldsmith BK. Psychosensory symptomatology in anticonvulsant-responsive psychiatric illness. Ann Clin Psychiatry 1991; 3: 27–35
139.
Hough C, Chuang DM. Carbamazepine acts through the peripheral benzodiazepine receptor to up-regulate β-adrenergic receptor mRNA. Soc Neurosci Abstracts 1995; 21: 1145
140.
Montezinho LP, Castro MM, Duarte CB, et al. The interaction between dopamine D2-like and beta-adrenergic receptors in the prefrontal cortex is altered by mood-stabilizing agents. J Neurochem 2006; 96: 1336–48PubMed
141.
Rubinow DR, Post RM, Gold PW, et al. Effect of carbamazepine on mean urinary free cortisol excretion in patients with major affective illness. Psychopharmacology (Berl) 1986; 88: 115–8
142.
Osuch EA, Cora-Locatelli G, Frye MA, et al. Post-dexamethasone cortisol correlates with severity of depression before and during carbamazepine treatment in women but not men. Acta Psychiatr Scand 2001; 104: 397–401PubMed
143.
Ketter TA, Kimbrell TA, George MS, et al. Baseline cerebral hypermetabolism associated with carbamazepine response, and hyponietabolism with nimodipine response in mood disorders. Biol Psychiatry 1999; 46: 1364–74PubMed
144.
Grof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002; 63: 942–7PubMed
145.
Frye MA, Altshuler LL, McElroy SL, et al. Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder. Am J Psychiatry 2003; 160: 883–9PubMed
146.
Malcolm R, Myrick H, Roberts J, et al. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med 2002; 17: 349–55PubMedPubMedCentral
147.
Ballenger JC, Post RM. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull 1984; 20: 572–84PubMed
148.
Stuppaeck CH, Pycha R, Miller C, et al. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol 1992; 27: 153–8PubMed
149.
Chu NS. Carbamazepine: prevention of alcohol withdrawal seizures. Neurol 1979; 29: 1397–401
150.
Malcolm R, Myrick H, Roberts J, et al. The differential effects of medication on mood, sleep disturbance, and work ability in outpatient alcohol detoxification. Am J Addict 2002; 11: 141–50PubMed
151.
Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000; 42 Suppl. 1: 2–10
152.
Okuma T, Yamashita I, Takahashi R, et al. Clinical efficacy of carbamazepine in affective, schizoaffective, and schizophrenic disorders. Pharmacopsychiatry 1989; 22: 47–53PubMed
153.
Post RM, Uhde TW. Anticonvulsants in non-epileptic psychosis. In: Trimble MR, Bolwig TG, editors. Aspects of epilepsy and psychiatry. Chichester: John Wiley and Sons, 1986: 177–212
154.
Carpenter Jr WT, Kurz R, Kirkpatrick B, et al. Carbamazepine maintenance treatment in outpatient schizophrenics. Arch Gen Psychiatry 1991; 48: 69–72PubMed
155.
Nachshoni T, Levin Y, Levy A, et al. A double-blind trial of carbamazepine in negative symptom schizophrenia. Biol Psychiatry 1994; 35: 22–6PubMed
156.
Yassa R, Dupont D. Carbamazepine in the treatment of aggressive behavior in schizophrenic patients: a case report. Can J Psychiatry 1983; 28: 566–8PubMed
157.
Patterson JF. Carbamazepine for assaultive patients with organic brain disease. Psychosomatics 1987; 28: 579–81PubMed
158.
Patterson JF. A preliminary study of carbamazepine in the treatment of assaultive patients with dementia. J Geriatr Psychiatry Neurol 1988; 1: 21–3PubMed
159.
Fichtner CG, Kuhlman DT, Gruenfeld MJ, et al. Decreased episodic violence and increased control of dissociation in a carbamazepine-treated case of multiple personality. Biol Psychiatry 1990; 27: 1045–52PubMed
160.
Coons PM. The use of carbamazepine for episodic violence in multiple personality disorder and dissociative disorder not otherwise specified: two additional cases. Biol Psychiatry 1992; 32: 717–20PubMed
161.
Keck PEJ, McElroy SL, Friedman LM. Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol 1992; 12: 36–41S
162.
Brady KT, Sonne SC, Malcolm RJ, et al. Carbamazepine in the treatment of cocaine dependence: subtyping by affective disorder. Exp Clin Psychopharmacol 2002; 10: 276–85PubMed
163.
Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079–88PubMed
164.
Calabrese JR, Keck Jr PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351–60PubMed
165.
March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005; 162: 836–46PubMed
166.
Brodie MJ, Kwan P. The star systems: overview and use in determining antiepileptic drug choice. CNS Drugs 2001; 15: 1–12PubMed
167.
Post RM, Ketter TA, Denicoff K, et al. Assessment of anticonvulsant drugs in patients with bipolar affective illness. In: Hindmarch I, Stonier PD, editors. Human psychopharmacology: methods and measures. Chichester: John Wiley & Sons, 1993: 211–45
168.
Obrocea GV, Dunn RM, Frye MA, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002; 51: 253–60PubMed
169.
Post RM, Kowatch RA. The heath care crisis of childhood onset bipolar illness: some recommendations for its amelioration. J Clin Psychiatry 2006; 67: 115–25PubMed
170.
Kowatch RA, Suppes T, Carmody TJ, et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2000; 39: 713–20PubMed
171.
Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomised, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006; 163(7): 1179–86PubMed
Metadaten
Titel
Thirty Years of Clinical Experience with Carbamazepine in the Treatment of Bipolar Illness
Principles and Practice
verfasst von
Robert M. Post
Prof. Terence A. Ketter
Thomas Uhde
James C. Ballenger
Publikationsdatum
01.01.2007
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 1/2007
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200721010-00005

Weitere Artikel der Ausgabe 1/2007

CNS Drugs 1/2007 Zur Ausgabe

Therapy in Practice

Pharmacological Management of Attention-Deficit Hyperactivity Disorder in Adolescents

Leading Article

Neurotensin Agonists

Original Research Article

Use of the Sustained Pain-Free Plus No Adverse Events Endpoint in Clinical Trials of Triptans in Acute Migraine

Adis Profile Report

Extended-Release Intramuscular Naltrexone in Alcohol Dependence in Adults: Profile Report

Leading Article

Mitochondrial Dysfunction as the Molecular Basis of Bipolar Disorder

Therapy in Practice

Restarting Clozapine after Neutropenia

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz

18.04.2024 | Spinale Muskelatrophien | Nachrichten

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Manche Gestagene können das Risiko für Meningeome erhöhen

15.04.2024 | Parkinson-Krankheit | Nachrichten

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest
weitere anzeigen

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise